Processa Pharmaceuticals, Inc. Common

PCSA

Processa Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing pharmaceutical products for serious and unmet medical conditions. The company emphasizes innovative drug development, often targeting niche markets with unmet needs, leveraging its expertise in formulation and clinical development processes.

$0.27 -0.00 (-1.44%)
🚫 Processa Pharmaceuticals, Inc. Common does not pay dividends

Company News

Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 Receptor Agonists, D2 Receptor Antagonists, and Others | DelveInsight
GlobeNewswire Inc. • Delveinsight • October 27, 2025

The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.

Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?
Benzinga • Mohd Haider • October 8, 2025

Processa Pharmaceuticals saw a significant stock price increase after initiating a Phase 2 clinical trial for next-generation capecitabine (NGC-Cap) as a potential treatment for advanced breast cancer, with interim results expected in mid-2025.

Spotting Penny Stocks Uptrends, 3 Top Tips
PennyStocks • J. Phillip • April 26, 2024

Here's how to spot penny stocks with potential uptrends The post Spotting Penny Stocks Uptrends, 3 Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Heatwurx Inc. (PCSA) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research • Zacks Equity Research • April 6, 2023

Heatwurx Inc. (PCSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Related Companies